Page 2443 - Williams Hematology ( PDFDrive )

2414 Index Index 2415

CHOP regimen (Cont.): Chronic graft-versus-host disease. prognosis
for peripheral T-cell lymphoma, See Graft-versus-host disease CD38 expression and, 1532
1694–1696, 1695t, 1697 (GVHD) CD49d expression and, 1532
poor clinical response to, 200 Chronic granulomatous disease cytogenetics and, 1531, 1531t
for posttransplant lymphoproliferative clinical features, 1030–1031, 1031t gene mutations and, 187, 223t
disorders, 1636 definition and history, 1027 immunoglobulin heavy-chain variable
for primary mediastinal large B-cell diagnostic classification, 1028t mutations and, 1531, 1531t
lymphoma, 1635 differential diagnosis, 1032 markers, 1532, 1532t
for T-cell-histiocyte-rich large B-cell epidemiology, 1027 ZAP-70 and, 1531–1532
lymphoma, 1637 etiology and pathogenesis, 1027 staging, 1532–1533, 1533t
for Waldenström macroglobulinemia, genetic alterations affecting cytochrome treatment, 1533–1540
1794–1795 b, 1029 alkylating agents, 1534
Chorea-acanthocytosis syndrome, 681 genetic alterations affecting cytosolic antibody therapy, 1535–1536
CHR (complete hematologic response), proteins, 1029 assessment of response, 1540
1452t NADPH-oxidase function, 1027–1029, B-cell receptor kinase inhibitors, 1538
Ch/Rg blood group, 2345t 1028f blinatumomab, 1539
Christmas disease/Christmas factor predisposition to infection, 1029–1030, chemoimmunotherapy, 1537
deficiency. See Hemophilia B 1030f, 1031t chimeric antigen receptor-T cells, 415,
Christmas factor. See Factor IX laboratory features, 1031–1032 1539
Chromatin neutrophil abnormalities in, 984t, 986 combination chemotherapy, 1534–1535
in blood cell differentiation, 166–167 therapy, course, prognosis, 1032 cyclin-dependent kinase inhibitors, 218,
gain-of-function mutations, 170 Chronic idiopathic neutropenia, 983, 985, 987 1539
genome access and, 166, 166f Chronic inflammation, 290–291 gene therapy, 438, 442
loss-of-function mutations, 170 Chronic kidney disease, anemia of. See glucocorticoids, 1536–1537
next-generation sequencing–based studies, Anemia of chronic kidney disease hematopoietic cell transplantation, 1539
161–162 Chronic lymphocytic leukemia (CLL) ibrutinib, 342
transcription factors and, 165–166, 168, chronic myelogenous leukemia and, 1449 initial, 1540
169f clinical features, 1530 lenalidomide, 1538–1539
Chromium, in red cell labeling, 488, 495–496, complications leukapheresis, 1540
497 autoimmune hemolytic anemia, 824, minimal residual disease evaluation,
Chromodomain (CHD)-family remodelers, 827, 831, 839, 840, 1541 1540
166, 166f immune thrombocytopenic purpura, nucleoside analogues, 1534
Chromosomal abnormalities 1541–1542 radiation therapy, 1540
analytic techniques, 174–176, 176f infectious, 1541 for relapsed disease, 1540
in hematologic and lymphoid pure red cell aplasia, 1542 splenectomy, 1539
malignancies, 176–188, 179–180t, Richter syndrome, 1542 venetoclax, 1539
184–185t, 219, 220–225t, 225, 230. secondary cancer risk, 1541 Chronic lymphoproliferative disorders of NK
See also specific diseases small lymphocytic lymphoma, 1543 cells (CLPD-NK)
nomenclature, 174, 175t definition, 1527 clinical features, 1566
Chromosomal instability syndromes. See differential diagnosis, 1200, 1543, 1655 definition and history, 1563
Immunodeficiency diseases, epidemiology, 1527 etiology and pathogenesis, 1563–1564
chromosomal instability etiology and pathogenesis gene mutations, 1564
syndromes associated with B-cell receptor pathway, 1528–1529 immunophenotypic features, 1565
Chronic basophilic leukemia, 1279, 1468t, chromosomal abnormalities, 185t, 187, Chronic mountain sickness, 875
1470 210, 223t, 1494t, 1529 Chronic myelogenous (myeloid) leukemia
Chronic cyclic neutropenia, 983, 985 disease biology, 1528 (CML), 1437–1473
Chronic eosinophilic leukemia, 1469–1470. environmental factors, 1528 accelerated phase and blast crisis
See also Hypereosinophilic gene mutations, 231–232t, 1349, 1494t, clinical features, 1465
syndromes 1528, 1592 course and prognosis, 1467
clinical features, 1469 immune dysregulation, 1528, 1592 cytogenetics, 1466
course and prognosis, 1470 laboratory findings definition, 1464
differential diagnosis, 1469–1470 blood, 1494t, 1530–1531, 1531f extramedullary blast crisis, 1465
etiology and pathogenesis, 1279, 1468t histopathology, 1592–1593, 1592f laboratory features, 1465
history and definition, 1469 marrow, 36f, 37 marrow blast crisis, 1465–1466
laboratory features, 1467, 1469–1470 monoclonal B-cell lymphocytosis and, pathogenesis, 1464–1465
therapy, 977, 1470 1200, 1542–1543 treatment, 1466–1467

Kaushansky_index_p2393-2506.indd 2414 9/21/15 3:21 PM